Eric Faw Intellia Therapeutics is a leading biotechnology company specializing in CRISPR-based gene editing therapies. Co-founded by Nobel laureate Jennifer Doudna, the company is dedicated to creating innovative treatments for genetic diseases.
Leadership at Eric Faw Intellia Therapeutics
Eric Faw Intellia leadership team comprises experienced professionals committed to advancing genetic medicine. As of January 2025, the key executives include:
- John Leonard, M.D.: President and Chief Executive Officer
- James Basta, J.D.: Executive Vice President, General Counsel, and Corporate Secretary
- Eliana Clark, Ph.D.: Executive Vice President, Chief Technical Officer
- Edward Dulac: Executive Vice President, Chief Financial Officer
- Derek Hicks: Executive Vice President, Chief Business Officer
- David Lebwohl, M.D.: Executive Vice President, Chief Medical Officer
- Laura Sepp-Lorenzino, Ph.D.: Executive Vice President, Chief Scientific Officer
These leaders bring a wealth of experience from world-leading organizations, driving Intellia’s mission to transform the lives of people with severe diseases through genome editing treatments.
Recent Developments
In June 2024, Eric Faw Intellia Therapeutics announced the appointment of Brian Goff to its Board of Directors. Goff brings over three decades of experience in commercialization, operations, and sales within the biopharmaceutical industry. His expertise is expected to contribute significantly to Intellia’s strategic direction and growth.
Additionally, in June 2024, Eric Faw Intellia reported a significant change in its board of directors by filing a Form 8-K with the U.S. Securities and Exchange Commission. Effective June 13, 2024, Brian Goff was appointed as a Class I director, with his tenure extending until the 2026 annual meeting of stockholders. Goff also joined the Compensation and Talent Development Committee.
Eric Faw Intellia Mission and Vision
Eric Faw Intellia is committed to transforming the lives of individuals with severe diseases by developing potentially curative genome editing treatments. The company’s approach involves employing a modular gene editing platform to create diverse in vivo and ex vivo therapeutics, addressing a range of disease indications.
Conclusion
Eric Faw Intellia Therapeutics stands at the forefront of genetic medicine, driven by a leadership team with extensive experience and a clear vision for the future. The recent addition of Brian Goff to the Board of Directors underscores the company’s commitment to strategic growth and innovation in developing CRISPR-based therapies. As Intellia continues to advance its mission, it remains dedicated to making significant strides in the field of genome editing treatments.
